Table 1.
Clinical characteristics of study participants by study (n = 5545)
| Characteristic | Overall | Australia |
Finland | United States |
United Kingdom | Sweden |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APCS | MCCS | PCFS | ATBC | CPS-II | MEC | PLCO | ICR | CAPS | PROCAP | STHM1 | STHM2 | ||
| Total No. | 5545 | 219 | 413 | 442 | 916 | 360 | 203 | 394 | 1061 | 690 | 248 | 205 | 394 |
| Aggressive, No. | 2770 | 219 | 114 | 198 | 466 | 169 | 106 | 190 | 530 | 452 | 31 | 67 | 228 |
| Age at dx, mean (SD) | 66.1 (8.8) | 64.9 (5.8) | 70.6 (7.4) | 57.9 (8.4) | 70.4 (6.1) | 73.3 (6.9) | 70.7 (9.0) | 70.1 (6.4) | 57.1 (5.2) | 67.3 (7.6) | 63.2 (5.2) | 69.6 (7.6) | 70.0 (8.7) |
| Family history, No. (%)a | |||||||||||||
| Yes | 331 (11.9) | 0 (0) | 15 (13.2) | 32 (16.2) | 27 (5.8) | 22 (13.0) | 6 (5.7) | 18 (9.5) | 111 (20.9) | 79 (17.5) | 10 (32.3) | 11 (16.4) | 0 (0) |
| No | 1776 (64.1) | 2 (0.9) | 67 (58.8) | 137 (69.2) | 380 (81.5) | 147 (87.0) | 90 (84.9) | 168 (88.4) | 351 (66.2) | 373 (82.5) | 6 (19.4) | 55 (82.1) | 0 (0) |
| Death from PCa, No. (%)a | |||||||||||||
| Yes | 2052 (74.1) | 21 (9.6) | 89 (78.1) | 156 (78.8) | 386 (82.8) | 127 (75.1) | 61 (57.5) | 117 (61.6) | 530 (100.0) | 362 (80.1) | 31 (100.0) | 66 (98.5) | 106 (46.5) |
| No | 311 (11.2) | 0 (0) | 0 (0) | 0 (0) | 80 (17.2) | 0 (0) | 18 (17.0) | 0 (0) | 0 (0) | 90 (19.9) | 0 (0) | 1 (1.5) | 122 (53.5) |
| Metastatic disease, No. (%)a | |||||||||||||
| Yes | 467 (16.9) | 4 (1.8) | 17 (14.9) | 10 (5.1) | 186 (39.9) | 0 (0) | 29 (27.4) | 47 (24.7) | 174 (32.8) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| No | 663 (23.9) | 3 (1.4) | 0 (0) | 1 (0.5) | 234 (50.2) | 0 (0) | 74 (69.8) | 131 (68.9) | 220 (41.5) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Stage, No. (%)a | |||||||||||||
| 1 | 410 (14.8) | 14 (6.4) | 59 (51.8) | 109 (55.1) | 63 (13.5) | 77 (45.6) | 31 (29.2) | 25 (13.2) | 16 (3.0) | 0 (0) | 4 (12.9) | 12 (17.9) | 0 (0) |
| 2 | 367 (13.2) | 0 (0) | 2 (1.8) | 10 (5.1) | 109 (23.4) | 0 (0) | 0 (0) | 36 (18.9) | 66 (12.5) | 71 (15.7) | 27 (87.1) | 15 (22.4) | 31 (13.6) |
| 3 | 1277 (46.1) | 194 (88.6) | 34 (29.8) | 67 (33.8) | 91 (19.5) | 92 (54.4) | 43 (40.6) | 77 (40.5) | 164 (30.9) | 315 (69.7) | 0 (0) | 33 (49.3) | 167 (73.2) |
| 4 | 654 (23.6) | 11 (5.0) | 19 (16.7) | 12 (6.1) | 203 (43.6) | 0 (0) | 29 (27.4) | 52 (27.4) | 230 (43.4) | 64 (14.2) | 0 (0) | 4 (6.0) | 30 (13.2) |
| Gleason score, No (%)a | |||||||||||||
| ≤6 | 197 (7.1) | 0 (0) | 4 (3.5) | 1 (0.5) | 109 (23.4) | 22 (13.0) | 4 (3.8) | 28 (14.7) | 9 (1.7) | 18 (4.0) | 0 (0) | 0 (0) | 2 (0.9) |
| 7 | 490 (17.7) | 2 (0.9) | 28 (24.6) | 80 (40.4) | 88 (18.9) | 36 (21.3) | 27 (25.5) | 38 (20.0) | 16 (3.0) | 133 (29.4) | 9 (29.0) | 0 (0) | 33 (14.5) |
| 8-10 | 1862 (67.2) | 217 (99.1) | 70 (61.4) | 115 (58.1) | 134 (28.8) | 82 (48.5) | 67 (63.2) | 114 (60.0) | 484 (91.3) | 299 (66.2) | 22 (71.0) | 67 (100.0) | 191 (83.8) |
| Nonaggressive, No. | 2775 | 0 | 299 | 244 | 450 | 191 | 97 | 204 | 531 | 238 | 217 | 138 | 166 |
| Age at dx, mean (SD) | 67.5 (7.0) | — | 71.5 (6.7) | 65.0 (6.5) | 71.9 (4.7) | 68.3 (5.0) | 67.8 (6.8) | 68.4 (5.5) | 62.6 (6.0) | 66.9 (7.4) | 63.7 (5.1) | 73.4 (3.8) | 67.0 (7.9) |
| Family history, No. (%)a | |||||||||||||
| Yes | 467 (16.8) | — | 47 (15.7) | 56 (23.0) | 17 (3.8) | 53 (27.7) | 14 (14.4) | 20 (9.8) | 123 (23.2) | 50 (21.0) | 58 (26.7) | 29 (21.0) | 0 (0) |
| No | 1816 (65.4) | — | 199 (66.6) | 137 (56.1) | 385 (85.6) | 138 (72.3) | 80 (82.5) | 181 (88.7) | 350 (65.9) | 188 (79.0) | 49 (22.6) | 109 (79.0) | 0 (0) |
| Stage, No. (%) | |||||||||||||
| 1 | 2383 (85.9) | — | 262 (87.6) | 198 (81.1) | 267 (59.3) | 191 (100.0) | 97 (100.0) | 78 (38.2) | 531 (100.0) | 238 (100.0) | 217 (100.0) | 138 (100.0) | 166 (100.0) |
| 2 | 392 (14.1) | — | 37 (12.4) | 46 (18.9) | 183 (40.7) | 0 (0) | 0 (0) | 26 (61.8) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Gleason score ≤6, No. (%)a | 2773 (99.9) | — | 299 (100.0) | 244 (100.0) | 450 (100.0) | 191 (100.0) | 97 (100.0) | 204 (100.0) | 531 (100.0) | 238 (100.0) | 217 (100.0) | 136 (98.6) | 166 (100.0) |
a
Numbers do not sum to the total sample size due to missing data. Dx = diagnosis; PCa = prostate cancer; APCS = Aggressive Prostate Cancer Case-Control Study; MCCS = Melbourne Collaborative Cohort Study; PCFS = Australian Prostate Cancer Family Study; ATBC = Alpha-Tocopherol, Beta-Carotene Prevention Study; CPS-II = American Cancer Society Cancer Prevention Study II; MEC = Multiethnic Cohort; PLCO = The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Cohort; ICR = The Institute of Cancer Research; CAPS = The Cancer of the Prostate in Sweden Study; PROCAP = Progression of Cancer in the Prostate; STHM1 = The Stockholm-1 Study; STHM2 = The Stockholm-2 Study; Em dash (—) = missing.